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Abstract—Diseases which are prevalent in the gastrointestinal 
(GI) tract, such as Crohn’s disease, are a topic of increasing 
concern because diagnosis and specific treatment are difficult and 
may be ineffective. New techniques are therefore sought after and 
this paper describes a proof-of-concept tethered capsule for 
targeted drug delivery (TDD) in the GI tract. The capsule consists 
of a camera, illumination, a drug delivery channel and an 
ultrasound (US) transducer. The transducer is described in detail, 
including a comparison of different piezoceramic materials that 
has been carried out. It was found that PZ54 (Ferroperm 
Piezoceramics, Kvistgaard, Denmark) was the most suitable 
material for our application. When driven at 4 Vpp, the outer 
diameter 5 mm PZ54 transducer operates at a frequency f = 4.05 
MHz providing an acoustic pressure, Pac = 125 kPa, with a beam 
diameter, BD = 0.75 mm at the focus. Pressures in the range 50 – 
300 kPa have been previously reported as suitable for 
sonoporation, a process vital in many TDD applications, so this is 
a promising result. Basic functional testing of the capsule was 
performed by supplying glass microbubbles (MBs) through the 
drug delivery channel into the US focus, monitored via the on-
board camera. It was found that the acoustic radiation forces have 
a clear influence on the MBs, significantly changing their direction 
at the US focus. This suggests that drugs may be targeted to 
specific tissue in the GI tract by the new capsule. The results 
translate into a capsule configuration with the potential to be 
clinically and biologically useful. 
Keywords—Therapeutic Capsule; Targeted Drug Delivery; 
Ultrasound Capsule; Capsule Endoscopy; UmTDD; GI Drug 
Delivery 
I.  INTRODUCTION  
  Capsule endoscopy (CE) for diagnosis in the gastrointestinal 
(GI) tract has emerged over the last fifteen years.  Now 
established in commercial products from companies such as 
Olympus (Olympus Corporation, Tokyo, Japan) and Covidien 
(Covidien Ltd., Dublin, Republic of Ireland) and documented as 
having benefitted more than one million patients, it is a clear 
candidate for further innovation for both diagnosis and therapy. 
     Ultrasound (US) is used extensively in medicine as a 
minimally-invasive and low-cost diagnostic imaging tool. Over 
the last few decades, there has been a growing research interest 
in the use of US in therapeutic applications, such as focused 
ultrasound (FUS) surgery and ultrasound-mediated targeted 
drug delivery (UmTDD) [1 - 2]. An additional beneficial factor 
in drug delivery (DD) applications is the inclusion of gas-filled 
microbubbles. These microbubbles, whose initial application 
was as an agent for imaging contrast enhancement, become 
active when sonicated, inducing US cavitation. This has the 
potential to cause clinically useful biological effects such as 
shock waves and sonoporation, which can, in turn, increase cell 
membrane permeability to bioactive materials [3 - 4]. 
     In UmTDD, microbubbles loaded with drugs or 
nanoparticles and used in combination with US have been 
shown to facilitate cellular delivery and uptake [3, 5 - 7]. 
Moreover, applying US in the presence of microbubbles has 
been shown to simultaneously increase cell membrane 
permeability, i.e. Sonoporation, and release or trigger 
therapeutic drugs at the target site. This has potential for 
minimally-invasive and localised therapy greatly increasing the 
efficacy of the drug or agent at the target site while 
simultaneously reducing unwanted systemic effects such as 
toxicity to healthy tissue [6, 8 - 10]. 
     Taking this into consideration, the aim of the work described 
here was to design, construct and test a proof-of-concept 
capsule for the therapy of GI conditions such as Crohn’s 
disease. In this capsule, the applied US would have three 
functions: to direct drugs and their packaging to the target, to 
release the drugs from the packaging, and to increase uptake 
through sonoporation. Here, the components in the capsule will 
be discussed in turn, with a detailed focus on the transducer, 
comparing different piezoceramic materials considered for 
inclusion in the capsule. 
 
II. MATERIALS AND METHODS 
This section describes the comparison between the 
piezoceramics considered for the transducer and outlines the 
transducer fabrication process. The design of the capsule and a 
discussion of the remaining components are provided. This 
section is concluded by discussing the functional testing carried 
out with the capsule. 
A. Transducer Fabrication 
Different piezoceramic materials were identified as 
candidates for the transducer to be embedded in the capsule. 
The two materials chosen for further study were PZ54 and PZ26 
(Ferroperm Piezoceramics, Kvistgaard, Denmark). PZ54 is a 
piezoceramic specifically designed for FUS applications and 
PZ26 represents the piezoceramic material most commonly 
used in FUS applications. To better determine which material 
would be most suitable for capsule inclusion transducers were 
fabricated and characterised with both of them.  
The specific piezoceramic geometry studied is a self-
focusing bowl with an outer diameter, OD = 5 mm, and radius 
of curvature, Rc = 15 mm. The backing layer used for the 
transducer is a composite of microbubbles (K1 Glass Bubbles, 
3M) and epoxy (Epofix, Struers A/S, Denmark) mixed at a ratio 
3:1 by weight, formed into the desired shape by using a PTFE 
mould. The backing layer is formed so that the outer shell of the 
transducer has OD = 6 mm and length = 4 mm. The coaxial 
cable used to attach the transducer to the signal generator has 
diameter 300 µm, connected to the transducer with Ag-loaded 
epoxy and to the driving signal generator with a BNC 
connector. A fabricated transducer can be seen in Fig. 1 with 
backing layer and cable. 
B. Capsule Design and Components 
The capsule has four main features: FUS transducer, CMOS 
imaging camera and illumination, drug delivery channel and a 
tether for control. The design of the capsule is such that the 
transducer, camera and drug delivery channel are confocal at 
approximately 4 mm from the capsule perimeter. The reason the 
components are confocal at 4 mm is that this is the assumed 
location of the bowel wall. If the distance was any greater, the 
transducer might focus beyond the bowel wall, which could 
result in too low an intensity of US. Of course, this fixed focus 
may also cause problems if the bowel wall is irregular. 
The capsule was designed using SolidWorks (Dassault 
Systemes SolidWorks Corp., Velizy-Villacoublay, France) and 
3D printed using an Objet Connex 500 (Stratasys Ltd., 
Minnesota). The capsule is 10 mm in diameter and 30 mm in 
length, this size chosen so that the capsule is comparable in size 
with capsules used for video endoscopy and other purposes. 
The design of the capsule is shown in Fig. 2.  
The camera chosen for capsule inclusion is the Medigus 
Micro ScoutCAM 1.2 (micro ScoutCam™, Medigus Ltd., 
Israel) which has OD = 1.2 mm and length = 5 mm. The camera 
cable has a diameter of 0.8 mm. A dedicated digital signal 
processor controls the camera. The illumination consists of a 
printed circuit board (PCB) with four white light emitting 
diodes (LEDs) controlled by a direct current (DC) power 
supply. The PCB has OD = 7 mm and thickness = 2.2 mm, with 
a hole diameter = 1.4 mm in the centre for the camera to pass 
through. The drug delivery channel is a fine-bore polythene 
tubing with OD = 0.96 mm and is controlled by a syringe pump 
external to the capsule. These components can all be seen in 
Fig. 3. 
C. Functional Testing 
To assess the capsule’s functionality in UmTDD 
applications, tests were performed using the capsule set up as 
described above. 
In order to align the camera, air filled glass MBs were 
passed through the drug delivery channel and into the camera’s 
field of view. The camera was then adjusted until the 
microbubbles were central in the field of view. 
The main functionality test carried out was to pass MBs 
through the drug delivery channel and into the US focus, while 
their behaviour was observed with the camera. The MBs were 
used to simulate drug-filled MBs which are commonly used in 
UmTDD applications. If the US can move around MBs then this 
is an early indication of its potential to target the MBs at a 





Fig. 1: Fabricated PZ54 transducer with OD = 6 mm and length = 4 mm. 0.3 
mm coaxial cable attached. 
 
Fig. 2: Rendered CAD drawing of capsule. Components (from left-to-right) are: 
Transducer, Illumination, camera and tether with drug delivery channel. 
 
Fig. 3: Capsule components (from left-to-right) are: US transducer, Medigus 
Micro ScoutCam camera, illumination and drug delivery channel with red dye 
for visibility. 
III. RESULTS 
A. Characterisation Results and Transducer Comparison 
Characterisation of the PZ54 and PZ26 transducers is an 
important step because it allows further differentiation between 
the two transducers to determine the best candidate for inclusion 
in the capsule.  
The first step in the characterisation process is impedance 
spectroscopy, to identify the optimum frequency for driving the 
transducer, called the central driving frequency (CDF). The 
impedance was measured after each fabrication step using a 
4395A Impedance Analyser (Agilent Technology / Keysight, 
Santa Clara, CA, USA). It was found that the CDF of the PZ54 
transducer was 4.05 MHz, close to the figure stated by the 
manufacturer. The impedance magnitude of the fully fabricated 
transducer was found to be suitably close to the 50 Ω impedance 
of the wire so electrical impedance matching was not required. 
The next step in the characterisation process is US field 
mapping. This was carried out using a calibrated needle 
hydrophone (Precision Acoustics, Dorchester, UK) scanned in 
the US field in an acoustic scanning tank (Precision Acoustics, 
Dorchester, England). These measurements allowed the 
acoustic pressure from and beam diameter of the transducers to 
be determined. Both transducers were driven at their CDF with 
V = 4 Vpp from a signal generator with a 50 Ω output. The 
pressure mapping of the PZ54 transducer is shown in Fig. 4, 
indicating Pac = 125 kPa and focal beam diameter, BD = 0.75 
mm. In comparison, the PZ26 transducer provided Pac = 157 
kPa BD = 1.35 mm. 
At this stage, enough data was available for a useful 
comparison of the transducers. Literature states that pressures 
in the range 50 - 300 kPa are suitable for reversible 
sonoporation in the GI tract [11]. Both the PZ26 and PZ54 
transducers can provide pressures in this range. The PZ54 
transducer was therefore selected as its smaller BD would allow 
a smaller area to be sonicated. Also PZ54 is more suitable for 
FUS purposes because it has a higher permittivity than PZ26, 
making it better for electrical impedance matching. 
Further characterisation of the PZ54 transducer was then 
carried out with the next step using a thermal camera to measure 
the temperature rise of the transducer and cable during 
operation. The thermal camera was focused on the face of the 
transducer and the cable in turn; it was found that there was no 
significant temperature rise at the transducer face or along the 
cable.  
The final characterisation procedure was acoustic power 
measurement. This was carried out using a radiation force 
balance (Precision Acoustics, Dorchester, UK) awith the PZ54 
transducer driven at different input voltages. It was found that 
at driving the transducer at V = 4 Vpp, acoustic power = 20.45 
mW is produced which increases linearly up to P = 85 mW at 
V = 10 Vpp.  
B. Experimental Results 
It was also considered useful to carry out functional testing 
to show the influence of the acoustic radiation force from the 
PZ54 transducer on a stream of MBs from the drug delivery 
channel. The capsule was set up with the PZ54 transducer along 
with camera, illumination and DD channel. MBs were used as 
before, with an average diameter of 65 µm, delivered using a 
syringe pump (BRAUN perfusor FM Pump IV Infusion syringe 
pump B, Braun Medical Ltd., Sheffield, UK). The US transducer 
driven at 7 Vpp at CDF = 4.05 MHz and the corresponding results 
are shown in Fig. 5. Fig. 5 (left) shows the MBs approaching the 
US focus and Fig. 5 (right) shows the MBs after they have 
changed direction due to the acoustic radiation force. These 
results are promising as they highlight the influence of the US 
on the MBs. This shows early indication that this capsule 
configuration could be suitable for clinical procedures involving 
drug-loaded microbubbles being trapped against the bowel wall, 
releasing their contents into sonoporated cells due to the US 
force. 
 
Fig. 4: US pressure mapping which shows the PZ54 outputs and acoustic 
pressure, Pac = 125 kPa, with focal beam diameter, BD = 0.75 mm. 
 
Fig. 5: (Purple arrows in each case represents direction of travel of MBs) Left: 
MBs approaching US focus. Middle: MBs reaching the US focus, beginning to 
change direction. Right: MBs completely changing direction due to acoustic 
radiation forces.  
IV. CONCLUSION 
     This paper has discussed a proof-of-concept tethered capsule 
for therapy in the GI tract. The capsule has a diameter OD = 10 
mm and length = 30 mm, making it comparable in size with 
commercial capsules for video endoscopy. The capsule includes 
a camera with illumination, drug delivery channel and US 
transducer in a shell made with 3D printing.  
     Different transducers materials, PZ54 and PZ26, have been 
considered for capsule inclusion. Both transducers were 
characterised, beginning with electrical impedance 
measurements. From the impedance measurements it was found 
that both transducers have a CDF close to that stated by the 
manufacturer and it was found that no electrical impedance 
matching was required. US field mapping was then carried out 
and it was found that, when driving the transducer at 4 Vpp, the 
PZ54 transducer has an acoustic pressure, Pac = 125 kPa and 
focal BD = 0.75 mm while the PZ26 transducer has Pac = 157 
kPa and focal BD = 1.35 mm. The pressure outputs are in the 
50 kPa - 300 kPa range suitable for Sonoporation in the GI tract 
[11], a process which plays a key role in many UmTDD 
procedures.  
     At this stage the PZ54 transducer was chosen for capsule 
inclusion, mainly because of its narrower BD resulting in a 
smaller area of sonication but also since PZ54 has a higher 
permittivity than PZ26 making it better for FUS. Further 
characterisation of the PZ54 transducer was then carried out. 
Thermal testing showed that the transducer and cable do not 
heat up significantly at 4 Vpp. Acoustic power measurements 
were also carried out and at 4 Vpp an output acoustic power = 
20.45 mW was recorded. 
     Once characterisation of the transducer was complete, the 
capsule was assembled for functional testing. The most 
important test involved glass MBs flowing through the drug 
delivery channel into the US focus, with their behaviour 
monitored using the camera. It was found that the PZ54 
transducer the behaviour of the MBs using the camera. It was 
found that the PZ54 transducer had the ability to alter the 
direction of travel of the MBs, promising results for drug 
delivery applications. 
     The two main results; the acoustic pressure being suitable 
for sonoporation in the GI tract and the transducer able to affect 
the MB egress suggests that a capsule configured as we have 
has potential in biomedical and drug delivery applications. 
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